Sinovac H1 2026: Revenue Up 13%, Net Loss Widens to $60.2M; Rabies Vaccine Approved

summarizeSummary

Sinovac reported H1 2026 revenue of $147.1 million, up 13% year-over-year, but net loss attributable to common shareholders widened to $60.2 million. The company also announced NMPA approval of its rabies vaccine and priority review for its HFMD2 vaccine.

check_boxKey Events · Earnings and Guidance · SVA

• H1 Revenue Up 13%

  Sales reached $147.1 million, driven by an 82.3% increase in overseas revenue to $66.5 million, now 45.2% of total sales.

• Net Loss Widens

  Net loss attributable to common shareholders was $60.2 million ($0.84 per share), up from $21.7 million ($0.30 per share) in H1 2025, mainly due to higher losses at majority-owned subsidiaries and lower investment income.

• Gross Margin Improves

  Gross margin rose to 65.0% from 62.5%, reflecting a favorable shift toward higher-margin international sales and cost efficiencies.

• Rabies Vaccine Approved

  NMPA approved PVRV-SF on August 4, 2026; the company plans to submit a WHO prequalification application and has a supply agreement with Brazil's Ministry of Health.

auto_awesomeAnalysis · SVA · Life Sciences

Sinovac's first-half results show a mixed picture: revenue grew 12.9% to $147.1 million on strong overseas sales, but net loss attributable to common shareholders widened to $60.2 million from $21.7 million a year earlier. The loss increase stems from higher losses at majority-owned subsidiaries and lower investment income, not from deteriorating operations. Gross margin improved to 65.0% from 62.5%, and R&D spending fell sharply. The company also announced NMPA approval of its rabies vaccine and priority review for its HFMD2 vaccine, which could become the world's first approved bivalent enterovirus vaccine. Cash remains substantial at $998.5 million, though operating cash burn was $321.8 million.